ITEM 2.
Managements Discussion and Analysis of Financial Condition and Results of
Operations
Except
for the historical information herein, the discussion in this quarterly report
on Form 10-Q contains forward-looking statements that involve risks and
uncertainties. These statements include projections about our accounting and
finances, plans and objectives for the future, future operating and economic
performance and other statements regarding future performance. These statements
are not guarantees of future performance or events. Our actual results may
differ materially from those discussed here. Factors that could cause or
contribute to differences in our actual results include those discussed under
the caption Cautionary Factors That May Affect Future Results, as well as
those discussed elsewhere in this quarterly report on Form 10-Q or in our other
public disclosures. You should consider carefully those cautionary factors,
together with all of the other information included in this quarterly report on
Form 10-Q. Each of the cautionary factors, either alone or taken together,
could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our common stock.
There may be additional risks that we are not presently aware of or that we
currently believe are immaterial which could also impair our business and
financial position. We disclaim any obligation to update these forward-looking
statements.
Overview
Amylin
Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the
lives of people with diabetes, obesity and other diseases through the
discovery, development and commercialization of innovative medicines. We have
developed and gained approval for two first-in-class medicines to treat
diabetes, BYETTA
®
(exenatide) injection and SYMLIN
®
(pramlintide acetate) injection, both of which were commercially launched in
the United States during the second quarter of 2005. BYETTA has also been
approved in the European Union, or EU, and the first commercial launch occurred
in Germany in April 2007 through our collaboration partner Eli Lilly and
Company, or Lilly. Lilly has launched, and we expect Lilly to continue to
launch, BYETTA in additional EU member states and other countries during 2007.
We also have two late-stage programs in development and multiple early-stage
programs. BYETTA is the first and only approved medicine in a new class of
compounds called incretin mimetics. We began selling BYETTA in the United
States in June 2005. BYETTA is approved in the United States for the
treatment of patients with type 2 diabetes who have not achieved adequate
glycemic control and are taking metformin, sulfonylurea and/or a
thiazolidinedone, or TZD, common oral therapies for type 2 diabetes. Net
product sales of BYETTA were $161.1 million and $126.4 million for the three
months ended September 30, 2007 and 2006, respectively, and $459.7 million and
$293.2 million for the nine months ended September 30, 2007 and 2006,
respectively.
We
have an agreement with Lilly for the global development and commercialization
of exenatide. This agreement includes BYETTA and any long-acting release
formulations of exenatide such as exenatide LAR, our once-weekly formulation of
exenatide for the treatment of type 2 diabetes. Under the terms of the
agreement, operating profits from products sold in the United States are shared
equally between Lilly and us. The agreement provides for tiered royalties
payable to us by Lilly based upon the annual gross margin for all exenatide
product sales, including any long-acting release formulations, outside of the
United States. Royalty payments for exenatide product sales outside of the
United States will commence after a one-time cumulative gross margin threshold
amount has been met. We expect royalty payments to commence in 2009. Lilly is
responsible for 100% of the costs related to development of twice-daily BYETTA
for sale outside of the United States. Development costs related to all other
exenatide products for sale outside of the United States will continue to be
allocated 80% to Lilly and 20% to us. Lilly will continue to be responsible for
100% of the costs related to commercialization of all exenatide products for
sale outside of the United States.
SYMLIN
is the first and only approved medicine in a new class of compounds called
amylinomimetics. We began selling SYMLIN in the United States in April 2005
for the treatment of patients with either type 1 or type 2 diabetes who are
treated with mealtime insulin but who have not achieved adequate glycemic
control. In October 2007 we received approval from
the U.S. Food and
Drug Administration, or FDA, for the SymlinPen
(TM)
120 and the
SymlinPen
(TM)
60 pen-injector devices for administering SYMLIN
injection.
In October 2007, the
FDA issued a Not Approvable letter for SYMLIN use with basal insulin (without
mealtime insulin) in patients with type 2 diabetes. We intend to initiate
discussions with the FDA to clarify further requirements for this approval. Net
product sales of SYMLIN were $16.3 million and $12.4 million for the three
months ended September 30, 2007 and 2006, respectively, and $47.0 million and
$30.3 million for the nine months ended September 30, 2007 and 2006,
respectively.
We
have a field force of approximately 580 people dedicated to marketing BYETTA
and SYMLIN in the United States. Our field force includes our specialty and
primary care sales forces and field management, a managed care and government
affairs organization, a medical science organization and diabetes care
specialists. Lilly co-promotes BYETTA in the United States and has primary
responsibility for developing and commercializing BYETTA outside of the United
States, including any long-acting release formulations.
12
In
addition to our marketed products, we have several programs in development,
including late-stage programs
for
diabetes and obesity.
In
diabetes, we are working with Lilly and Alkermes, Inc., or Alkermes, to develop
exenatide LAR. We recently completed a clinical study evaluating exenatide LAR
in patients with type 2 diabetes that is designed to generate the type of safety
and efficacy data that could form the basis of a New Drug Application, or NDA,
submission to the FDA. On October 31, 2007 we announced positive results from
this 30-week comparator study of once-weekly exenatide long-acting release LAR
injection and BYETTA taken twice daily in patients with type 2 diabetes.
Once-weekly exenatide, an investigational drug, showed a statistically
significant improvement in A1C of approximately 1.9 percentage points from
baseline, compared to an improvement of approximately 1.5 percentage points for
BYETTA. Approximately three out of four subjects treated with once-weekly
exenatide achieved an A1C of 7 percent or less. A1C of less than 7 percent is
the target for good glucose control as recommended by the American Diabetes Association
. In addition, we and Lilly are working with Alkermes and Parsons, Inc.
on the construction of a manufacturing facility for exenatide LAR in Ohio. We
expect to complete the commercial scale manufacturing process in this facility
in the second half of 2008.
We
have multiple early-stage programs for diabetes and obesity. We have a number
of compounds in development for the potential treatment of obesity which are
part of a broader program which we refer to as INTO: Integrated Neurohormonal
Therapies for Obesity. As part of this program, we are currently conducting
several clinical trials of our drug candidates, or combinations of our drug
candidates. We also maintain an active discovery research program focused on
novel peptide therapeutics. We are actively seeking to in-license additional
drug candidates. We have partnered with PsychoGenics, Inc., to form Psylin
Neurosciences, Inc., or Psylin, a company that will focus on the discovery and
development of peptide hormones for treatment of psychiatric indications. During
the second quarter of 2007, we made a strategic equity investment in BioSeek,
Inc., or BioSeek, a company that specializes in predictive human cell-based
disease models, and contracted with BioSeek to assess the potential utility of
Amylins peptide hormones in immune/inflammatory disorders.
Since
our inception in September 1987, we have devoted substantially all of our
resources to our research and development programs and, more recently, to the
commercialization of our products. All of our revenues prior to May 2005
were derived from fees and expense reimbursements under our BYETTA
collaboration agreement with Lilly, previous SYMLIN collaborative agreements
and previous co-promotion agreements. During the second quarter of 2005, we began
to derive revenues from product sales of BYETTA and SYMLIN. We have been unprofitable since inception and
may incur additional operating losses for at least the next few years.
At September 30, 2007, our accumulated deficit was approximately $1.4 billion.
At September 30, 2007, we had approximately $1.1 billion in cash, cash
equivalents and short-term investments. We may not generate positive operating
cash flows for at least the next few years and accordingly, we may need to raise additional funds from outside
sources. Refer to the discussions under the headings Liquidity and
Capital Resources below and Cautionary Factors That May Affect Future
Results in Part II, Item 1A for further discussion regarding our anticipated
future capital requirements.
Application
of Critical Accounting Policies
Our
discussion and analysis of financial condition and results of operations are
based upon our consolidated financial statements, which have been prepared in
accordance with U.S. generally accepted accounting principles. The preparation
of these financial statements requires us to make significant estimates and
judgments that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosures. On an on-going basis, we evaluate our
estimates, and actual results, however, may differ significantly from our
estimates.
The
financial information as of September 30, 2007, should be read in conjunction
with the financial statements for the year ended December 31, 2006, contained
in our annual report on Form 10-K filed on February 26, 2007.
For
a discussion of the Companys critical accounting policies, see Item 7.
Managements Discussion and Analysis of Financial Condition and Results of
Operations in our annual report on Form 10-K filed on February 26, 2007.
Results of Operations
Comparison of Three Months Ended September 30, 2007 to Three
Months Ended September 30, 2006
Net Product Sales
Net
product sales for the three months ended September 30, 2007 and 2006 were
$177.4 million and $138.8 million, respectively, and consisted of shipments of
BYETTA and SYMLIN, less allowances for product returns, rebates and wholesaler
chargebacks, wholesaler discounts, and prescription vouchers.
13
The
following table provides information regarding net product sales (in millions):
|
|
Three months ended September 30,
|
|
|
|
2007
|
|
2006
|
|
BYETTA
|
|
$
|
161.1
|
|
$
|
126.4
|
|
SYMLIN
|
|
16.3
|
|
12.4
|
|
|
|
$
|
177.4
|
|
$
|
138.8
|
|
The
increases in net product sales for BYETTA and SYMLIN in the current period,
both of which were launched in the United States during the second quarter of
2005, reflect continued growth in patient demand.
Revenues Under Collaborative
Agreements
Revenues under collaborative agreements for the three
months ended September 30, 2007, were $12.6
million
compared to $8.2 million for the same period in 2006. Substantially all of the
revenue recorded in these periods consists of amounts earned pursuant to our
BYETTA collaboration agreement with Lilly. The $4.4 million increase in
revenues under collaborative agreements in the current quarter compared to the
same period in 2006 reflects higher cost-sharing payments from Lilly due to
increased development expenses for exenatide LAR. The following table summarizes
the components of revenues under collaborative agreements for the three months
ended September 30, 2007 and 2006 (in millions):
|
|
Three months ended
September 30,
|
|
|
|
2007
|
|
2006
|
|
Amortization of up-front payments
|
|
$
|
1.1
|
|
$
|
1.1
|
|
Cost-sharing payments
|
|
11.5
|
|
7.1
|
|
|
|
$
|
12.6
|
|
$
|
8.2
|
|
In future periods, revenues under collaborative
agreements will consist of ongoing cost-sharing payments from Lilly to equalize
development costs, possible future milestone payments and the continued
amortization of the $30 million portion of the up-front payment received from
Lilly upon signing of our collaboration agreement in 2002. The amount of
cost-sharing revenue recorded will be dependent on the timing, extent and
relative proportion of total development costs for the exenatide LAR and BYETTA
development programs incurred by us and by Lilly. The receipt and recognition
as revenue of future milestone payments is subject to the achievement of
performance requirements underlying such milestone payments and, for certain
development milestones, the expiration of stock conversion rights associated
with such payments.
Cost of Goods Sold
Cost
of goods sold for the three months ended September 30, 2007 and 2006 was $13.8
million, representing a gross margin of 92%, and $14.5 million, representing a
gross margin of 90%, respectively, and is comprised primarily of manufacturing
costs associated with BYETTA and SYMLIN sales during the period. The
improvement in gross margin for the three months ended September 30, 2007
compared to the same period in 2006 primarily reflects a higher average net
sales price per unit for BYETTA and lower unit costs for BYETTA resulting from
higher production volumes. The increase in average net sales price per unit for
BYETTA is due to price increases, a change in product mix, and a decrease in
sales allowances. Quarterly fluctuations in gross margins may be influenced by
product mix, pricing, and the level of sales allowances.
Selling, General
and Administrative Expenses
Selling,
general and administrative expenses increased to $87.7 million for the three
months ended September 30, 2007, from $69.0 million for the same period in
2006. The increase primarily reflects higher promotional expenses for BYETTA
and SYMLIN, expenses associated with our expanded sales force, and increased
business infrastructure to support our growth.
Selling,
general and administrative expenses are expected to continue to increase during
the remainder of 2007, which reflects increased promotional expenses due primarily
to our and Lillys ongoing direct-to-consumer education program for BYETTA,
ongoing sales and marketing activities and expanded business infrastructure to
support our growth.
14
Research and
Development Expenses
Our
research and development expenses are comprised of salaries, benefits and
stock-based compensation, license fees, milestones under license agreements,
costs paid to third-party contractors to perform research, conduct clinical
trials, and develop drug materials and delivery devices, and a portion of our
facilities costs. We charge direct internal and external program costs to the
respective development programs. We also incur indirect costs that are not
allocated to specific programs because such costs benefit multiple development
programs and allow us to increase our pharmaceutical development capabilities.
These consist primarily of facilities costs and other internal shared resources
related to the development and maintenance of systems and processes applicable
to all of our programs.
Our
research and development efforts are focused on diabetes, obesity, and other
diseases. We also maintain an active discovery research program. In diabetes,
we have two approved products, BYETTA and SYMLIN, and we are developing
exenatide LAR, a long acting release formulation of exenatide, the active
pharmaceutical ingredient in BYETTA. In obesity, we have a number of compounds
in development for the potential treatment of obesity which are part of a broader
program which we refer to as INTO: Integrated Neurohormonal Therapies for
Obesity. As part of this program, we are currently conducting several clinical
trials of our drug candidates, or combinations of our drug candidates.
The following table provides information regarding
our research and development expenses for our major projects (in millions):
|
|
Three months ended September 30,
|
|
|
|
2007
|
|
2006
|
|
Increase
(Decrease)
|
|
Diabetes
|
|
$
|
34.4
|
|
$
|
24.5
|
|
$
|
9.9
|
|
Obesity
|
|
8.6
|
|
10.2
|
|
(1.6
|
)
|
Research and early-stage
programs
|
|
9.7
|
|
10.5
|
|
(0.8
|
)
|
Indirect costs
|
|
8.8
|
|
8.5
|
|
0.3
|
|
|
|
$
|
61.5
|
|
$
|
53.7
|
|
$
|
7.8
|
|
The $7.8 million increase in research and development
expenses for the three months ended September 30, 2007 as compared to the same
period in 2006 primarily reflects increased expenses of $9.9 million for our
diabetes programs, partially offset by decreased expenses for our obesity
programs, and research and early-stage programs. The increase in expenses for
our diabetes programs primarily reflects increased expenses for exenatide LAR
associated with manufacturing scale-up and the recently completed clinical
study discussed above.
Collaborative
Profit Sharing
Collaborative profit sharing was $75.0 million and
$57.0 million for the three months ended September 30, 2007 and 2006,
respectively, and consists of Lillys 50% share of the gross margin for BYETTA
in the United States.
Make-whole
Payment on Debt Redemption
In July 2006, we called for the redemption on August
24, 2006 of all our outstanding 2003 Notes under a provisional redemption based
upon the market price of our common stock exceeding certain thresholds.
All holders elected to convert their 2003 Notes into shares of our common
stock. In connection with the conversion, we issued approximately 5.6
million shares, including 180,005 shares as a make-whole payment, representing
$112.94 per $1,000 principal amount of the 2003 Notes converted less interest
actually paid.
During the quarter ended September 30, 2006 we
recorded a one-time, non-cash, non-operating charge of $7.9 million for a
make-whole payment associated with an early redemption of convertible senior
notes.
Interest and Other Income and
Expense
Interest and other income consist primarily of
interest income from investment of cash and other investments. Interest and
other income increased to $14.2 million for the three months ended September
30, 2007, from $10.7 million for the same period in 2006. The increase reflects
higher average investment balances due to proceeds of $559 million from our
2007 Notes issued in June 2007.
Interest and other expense
consist primarily of interest expense resulting from our long-term debt
obligations. Interest expense in the three months ended September 30, 2007
consists of interest on our $775 million of outstanding convertible senior
notes and the amortization of associated debt issuance costs.
Interest
and other expense was $6.1 million and $1.7
15
million for the three months ended September 30, 2007
and 2006, respectively. The increase reflects additional interest expense for
our 2007 Notes issued in June 2007.
Net Loss
Our net loss for the three months ended September
30, 2007 was $39.8 million compared to a net loss of $46.1 million for the same
period in 2006. The decrease in net loss primarily reflects the increased net
product sales and revenues under collaborative agreements, partially offset by
the increased selling, general and administrative expenses, increased research
and development expenses, and increased collaborative profit-sharing discussed
above. Net loss for the quarter ended September 30, 2006 also included a $7.9
million make-whole payment on debt redemption.
We may incur operating losses for the next few years.
Our ability to reach profitability in the future will be heavily dependent upon
the amount of product sales that we achieve for BYETTA and SYMLIN. In addition,
ongoing and potential increased expenses associated with the continued
commercialization of BYETTA and SYMLIN, and expenses associated with the
potential expansion of our research and development programs, including our
late-stage programs and our early-stage development programs, and related
support infrastructure, may impact our ability to reach profitability in the
future. Our operating results may fluctuate from quarter to quarter as a result
of differences in the timing of expenses incurred and revenues recognized.
Comparison of Nine Months Ended September 30, 2007 to
Nine Months Ended September 30, 2006
Net Product Sales
Net product sales for the nine months ended
September 30, 2007 and 2006 were $506.7 million and $323.5 million,
respectively, and consisted of shipments of BYETTA and SYMLIN, less allowances
for product returns, rebates and wholesaler chargebacks, wholesaler discounts,
and prescription vouchers.
The following table provides information regarding
net product sales (in millions):
|
|
Nine months ended September 30,
|
|
|
|
2007
|
|
2006
|
|
BYETTA
|
|
$
|
459.7
|
|
$
|
293.2
|
|
SYMLIN
|
|
47.0
|
|
30.3
|
|
|
|
$
|
506.7
|
|
$
|
323.5
|
|
The increases in net product sales for BYETTA and
SYMLIN in the current period, both of which were launched in the United States
during the second quarter of 2005, reflect continued growth in patient demand.
Revenues Under
Collaborative Agreements
Revenues
under collaborative agreements for the nine months ended September 30, 2007
were $52.2 million compared to $24.1 million for the same period in 2006.
Substantially all of the revenue recorded in these periods consists of amounts
earned pursuant to our BYETTA collaboration agreement with Lilly. The $28.1
million increase in revenues under collaborative agreements in the nine months
ended September 30, 2007 compared to the same period in 2006 reflects $15.0
million in milestone revenue associated primarily with Lillys launch of BYETTA
in the EU and higher cost-sharing payments due to increased development
expenses for exenatide LAR.
The
following table summarizes the components of revenues under collaborative
agreements for the nine months ended September 30, 2007 and 2006 (in millions):
|
|
Nine months ended
September 30,
|
|
|
|
2007
|
|
2006
|
|
Amortization of up-front payments
|
|
$
|
3.2
|
|
$
|
3.2
|
|
Milestones
|
|
15.0
|
|
|
|
Cost-sharing payments
|
|
34.0
|
|
20.9
|
|
|
|
$
|
52.2
|
|
$
|
24.1
|
|
16
Cost of Goods
Sold
Cost of goods sold for the nine months ended
September 30, 2007 and 2006 was $43.3 million, representing a gross margin of
91%, and $38.9 million, representing a gross margin of 88%, respectively, and
is comprised primarily of manufacturing costs associated with BYETTA and SYMLIN
sales during the period. The improvement in gross margin for the nine months
ended September 30, 2007 compared to the same period in 2006 reflects the same factors
that influenced similar fluctuations in the three months ended September 30,
2007 discussed above.
Selling, General and Administrative Expenses
Selling, general and administrative expenses
increased to $268.6 million for the nine months ended September 30, 2007, from
$192.4 million for the same period in 2006. The increase primarily reflects the same factors
that influenced similar fluctuations in the three months ended September 30,
2007 discussed above.
Research and Development Expenses
The following table provides information regarding
our research and development expenses for our major projects (in millions):
|
|
Nine months ended September 30,
|
|
|
|
2007
|
|
2006
|
|
Increase
|
|
Diabetes
|
|
$
|
97.4
|
|
$
|
72.3
|
|
$
|
25.1
|
|
Obesity
|
|
40.3
|
|
32.8
|
|
7.5
|
|
Research and
early-stage programs
|
|
28.9
|
|
28.0
|
|
0.9
|
|
Indirect costs
|
|
26.2
|
|
22.8
|
|
3.4
|
|
|
|
$
|
192.8
|
|
$
|
155.9
|
|
$
|
36.9
|
|
The $36.9 million increase in research and development
expenses for the nine months ended September 30, 2007 as compared to the same
period in 2006 primarily reflects increased expenses of $25.1 million for our
diabetes programs, and $7.5 million for our obesity programs. The increase in
expenses for our diabetes programs primarily reflects increased expenses for
exenatide LAR associated with manufacturing scale-up and the recently completed
clinical study discussed above. The increase in expenses for our obesity
programs primarily reflects expenses for ongoing clinical trials associated
with our INTO program.
Collaborative
Profit Sharing
Collaborative profit sharing was $212.3 million and
$130.4 million for the nine months ended September 30, 2007 and 2006,
respectively, and consists of Lillys 50% share of the gross margin for BYETTA
in the United States.
Interest and
Other Income and Expense
Interest and other income consist primarily of interest
income from investment of cash and other investments. Interest and other income
increased to $33.6 million for the nine months ended September 30, 2007, from
$24.5 million for the same period in 2006. The increase of $9.1 million is due
to higher interest rates received on our investments and higher average
investment balances in 2007 as compared to 2006.
Interest and other expense
consist primarily of interest expense resulting from our long-term debt
obligations. Interest expense in the nine months ended September 30, 2007
consists of interest on our $775 million of outstanding convertible senior
notes and the amortization of associated debt issuance costs.
Interest
and other expense was $9.7 million and $7.0 million for the nine months ended
September 30, 2007 and 2006, respectively. The increase in 2007 reflects higher
interest expense following the issuance of $575 million of 3.00% convertible
senior notes issued in June 2007, partially offset by lower interest expense
following the August 2006 conversion of $175 million of all outstanding 2.25%
convertible senior notes issued in 2003.
Net Loss
Our net loss for the nine months ended September 30,
2007 was $134.2 million compared to a net loss of $160.4 million for the same
period in 2006. The decrease in net loss primarily reflects the same factors that influenced
similar fluctuations in the three months ended September 30, 2007 discussed
above.
17
Liquidity
and Capital Resources
Since our inception, we have financed our operations
primarily through public sales and private placements of our common and
preferred stock, debt financings, payments received pursuant to our BYETTA
collaboration with Lilly, reimbursement of SYMLIN development expenses through
earlier collaboration agreements, and since the second quarter of 2005, through
product sales of BYETTA and SYMLIN.
At September 30, 2007, we had $1.1 billion in cash,
cash equivalents and short-term investments, compared to $767.3 million at December
31, 2006. We used cash of $87.7 million and $101.9 million for our operating
activities in the nine months ended September 30, 2007 and 2006, respectively. Our
cash used for operating activities in the nine months ended September 30, 2007
included uses of cash due to increases in current assets, consisting primarily
of an increase in inventories, of $44.2 million, offset by sources of cash due
to increases in accounts payable and accrued liabilities of $16.6 million,
payable to collaborative partner of $13.1 million, and other assets and
liabilities, net, of $14.7 million. The increase in inventories reflects
increased inventory purchases to support sales growth and investment in
inventory to support the planned launch of SYMLIN in a new pen delivery system.
The increase in accounts payable and accrued liabilities primarily reflects
increases for accrued interest related to our convertible debt and an increase
in accrued rebate discounts. The increase in payable to collaborative partner,
which represents Lillys 50% share of BYETTA gross margins in the United
States, primarily reflects increased net product sales for BYETTA. The increase
in other assets and liabilities, net, primarily represents an increase in
deferred rent due to expanded corporate facilities.
Our investing activities used cash of $261.4 million
and $357.9 million for the nine months ended September 30, 2007 and 2006,
respectively. Investing activities in both quarters consisted primarily of
purchases and sales of short-term investments and purchases of property, plant
and equipment and increases in other long-term assets. Purchases of property,
plant and equipment increased to $202.7 million for the nine months ended
September 30, 2007 from $51.5 million for the nine months ended September 30,
2006. The increase during the nine months ended September 30, 2007 primarily
reflects costs associated with our manufacturing facility for exenatide LAR
and, to a lesser extent, expenditures for tenant improvements, office equipment
and scientific equipment to support our growth. We expect that our capital
expenditures will continue to significantly increase in future periods due
primarily to costs associated with ongoing construction of our manufacturing
facility for exenatide LAR. We expect to complete the commercial-scale
manufacturing process in the second half of 2008. Through September 30, 2007,
we had incurred $237 million associated with the construction of this facility.
As previously disclosed, we are increasing our expenditures from $180 million
to an approximate total of $400 million over the next two years. The full
expansion of this project is dependent upon on the continued progress of
exenatide LAR through the development process. In addition, we anticipate
continued investments in tenant improvements, office equipment and scientific
equipment. We are evaluating various forms of secured debt financing to fund a
portion of the cost of our manufacturing facility. In addition, we are
evaluating the potential utility of other financing mechanisms, including
revolving credit lines or similar facilities, which may be secured by our
inventories, accounts receivable or other assets. The $12.6 million increase in
other long-term assets primarily reflects our investments in Psylin and
BioSeek.
Financing activities provided cash of $619.7 million
and $541.3 million for the nine months ended September 30, 2007 and 2006,
respectively. Financing activities for the nine months ended September 30, 2007
include $559 million in net proceeds from our issuance of $575 million in
aggregate principal amount of our 3.0% convertible senior notes due in 2014, or
the 2007 Notes, the exercise of stock options and proceeds from our employee
stock purchase plan.
At September 30, 2007, we had $200 million in
aggregate principal amount of our 2.5% convertible senior notes due in 2011, or
the 2004 Notes, and $575 million of the 2007 Notes outstanding. The 2004 Notes
are currently convertible into a total of up to 5.8 million shares of our
common stock at approximately $34.35 per share and are not redeemable at our
option. The 2007 Notes are currently convertible into a total of up to 9.4
million shares of our common stock at approximately $61.07 per share and are
not redeemable at our option.
18
The following table summarizes
our contractual obligations and maturity dates as of September 30, 2007 (in
thousands):
|
|
Payments Due by Period
|
|
Contractual Obligations
|
|
Total
|
|
Less than 1
year
|
|
1-3 years
|
|
4-5 years
|
|
After 5 years
|
|
Long-term debt
|
|
$
|
775,000
|
|
$
|
|
|
$
|
|
|
$
|
200,000
|
|
$
|
575,000
|
|
Interest payments on long-term
debt
|
|
141,085
|
|
22,585
|
|
44,500
|
|
39,500
|
|
34,500
|
|
Inventory purchase
obligations(1)
|
|
159,069
|
|
86,142
|
|
56,805
|
|
14,498
|
|
1,624
|
|
Operating lease obligations
|
|
129,261
|
|
16,840
|
|
29,873
|
|
28,552
|
|
53,996
|
|
Total(2)
|
|
$
|
1,204,415
|
|
$
|
125,567
|
|
$
|
131,178
|
|
$
|
282,550
|
|
$
|
665,120
|
|
(1) Includes
$102.7 million of outstanding purchase orders, cancelable by us upon 30 days
written notice, subject to reimbursement of costs incurred through the date of
cancellation.
(2) Excludes
long-term obligation of $9.1 million related to deferred compensation, the
payment of which is dependent upon elections made by participants that are
subject to change.
In addition, under certain license and collaboration
agreements we are required to pay royalties and/or milestone payments upon the
successful development and commercialization of related products. We expect to
make development milestone payments up to $9 million associated with licensing
agreements in the next 12 months. Additional milestones of up to approximately
$238 million could be paid over the next ten to fifteen years if development
and commercialization of all our early stage programs continue and are successful.
The significant majority of these milestones relate to potential future
regulatory approvals and subsequent sales thresholds. Given the inherent risk
in pharmaceutical development, it is highly unlikely that we will ultimately
make all of these milestone payments; however, we would consider these payments
as positive because they would signify that the related products are moving
successfully through development and commercialization.
Our future capital
requirements will depend on many factors, including: the amount of product
sales we achieve for BYETTA and SYMLIN; costs associated with the continued
commercialization of BYETTA and SYMLIN; costs associated with the establishment
of our exenatide LAR manufacturing facility; costs of potential licenses or
acquisitions; the potential need to repay existing indebtedness; costs
associated with an increase in our infrastructure; our ability to receive or
need to make milestone payments; our ability, and the extent, to which we
establish collaborative arrangements for SYMLIN or any of our product
candidates; progress in our research and development programs and the magnitude
of these programs; costs involved in preparing, filing, prosecuting,
maintaining, enforcing or defending our patents; competing technological and
market developments; and costs of manufacturing, including costs associated
with establishing our own manufacturing capabilities or obtaining and
validating additional manufacturers of our products; and scale-up costs for our
drug candidates.
ITEM 3.
Quantitative and Qualitative
Disclosures about Market Risk
We invest our excess cash
primarily in U.S. Government securities, asset-backed securities and debt
instruments of financial institutions and corporations with strong credit
ratings. These instruments have various short-term maturities. We do not
utilize derivative financial instruments, derivative commodity instruments or
other market risk sensitive instruments, positions or transactions in any
material fashion. Accordingly, we believe that, while the instruments held are
subject to changes in the financial standing of the issuer of such securities,
we are not subject to any material risks arising from changes in interest
rates, foreign currency exchange rates, commodity prices, equity prices or
other market changes that affect market risk sensitive investments. Our debt is
not subject to significant swings in valuation as interest rates on our debt
are fixed. The fair value of our 2004 Notes and 2007 Notes at September 30,
2007 was approximately $312.5 million and $629.8 million, respectively. A
hypothetical 1% adverse move in interest rates along the entire interest rate
yield curve would not materially affect the fair value of our financial
instruments that are exposed to changes in interest rates, which consists
primarily of debt securities in our short-term investment portfolio.
ITEM 4.
Controls and Procedures
As of September 30, 2007, an evaluation was
performed under the supervision and with the participation of our management,
including our President and Chief Executive Officer (referred to as our CEO)
and our Senior Vice President, Finance and Chief Financial Officer (referred to
as our CFO), of the effectiveness of the design and operation of our disclosure
controls and procedures. In designing and evaluating the disclosure controls
and procedures, management recognizes that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management necessarily is
required to apply its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Based on that evaluation, our management,
19
including
our CEO and CFO, concluded that our disclosure controls and procedures were
effective at a reasonable level of assurance as of September 30, 2007.
Our management does not expect that our disclosure
control and procedures or our internal control over financial reporting will
prevent all error and all fraud. A control system, no matter how well conceived
and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. Because of the inherent limitations
in all control systems, no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if any, or
misstatements due to error, if any, within the company have been detected.
While we believe that our disclosure controls and procedures and internal
control over financial reporting are and have been effective, in light of the
foregoing we intend to continue to examine and refine our disclosure controls
and procedures and internal control over financial reporting.
An evaluation was also performed under the supervision and with the
participation of our management, including our CEO and CFO, of any change in
our internal control over financial reporting that occurred during our last
fiscal quarter and that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting. That
evaluation did not identify any change in our internal control over financial
reporting that occurred during our latest fiscal quarter and that has
materially affected, or is reasonably likely to affect, our internal control
over financial reporting.
PART II. OTHER INFORMATION
1A. Risk Factors
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
The
following sets forth cautionary factors that may affect our future results,
including clarifications to the cautionary factors included in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2006 and our
subsequent filings with the Securities and Exchange Commission.
We have a history of operating losses, anticipate future losses and may
never become profitable.
We have experienced
significant operating losses since our inception in 1987, including losses of
$134.2 million for the nine months ended September 30, 2007, $218.9 million in
2006, $206.8 million in 2005 and $157.2 million in 2004. As of September 30,
2007, we had an accumulated deficit of approximately $1.4 billion. The extent
of our future losses and the timing of potential profitability are uncertain,
and we may never achieve profitable operations. We have been engaged in
discovering and developing drugs since inception, which has required, and will
continue to require, significant research and development expenditures. We
derived substantially all of our revenues prior to 2005 from development funding,
fees and milestone payments under collaborative agreements and from interest
income. BYETTA and SYMLIN may not be as commercially successful as we expect
and we may not succeed in commercializing any of our other drug candidates. We
may incur substantial operating losses for at least the next few years as we
continue to expand our commercial function for BYETTA and SYMLIN and our
research and development activities for the other drug candidates in our
development pipeline. These losses, among other things, have had and will have
an adverse effect on our stockholders equity and working capital. Even if we
become profitable, we may not remain profitable.
We began selling, marketing and distributing our first products, BYETTA
and SYMLIN, in 2005 and we will depend heavily on the success of those products
in the marketplace.
Prior to the launch of
BYETTA and SYMLIN in 2005, we had never sold or marketed our own products. Our
ability to generate product revenue for the next few years will depend solely on
the success of these products. The ability of BYETTA and SYMLIN to generate
revenue at the levels we expect will depend on many factors, including the
following:
acceptance
of these first-in-class medicines by the medical community, patients receiving
therapy and third party payors;
a
satisfactory efficacy and safety profile as demonstrated in a broad patient
population;
successfully
expanding and sustaining manufacturing capacity to meet demand;
the
competitive landscape for approved and developing therapies that will compete
with the products; and
our
ability to expand the indications for which we can market the products.
20
If we encounter safety issues with BYETTA or SYMLIN or any other drugs
we market or fail to comply with extensive continuing regulations enforced by
domestic and foreign regulatory authorities, it could cause us to discontinue
marketing those drugs, reduce our revenues and harm our ability to generate
future revenues, which would negatively impact our financial position.
BYETTA and SYMLIN, in
addition to any other of our drug candidates that may be approved by the FDA,
will be subject to continual review by the FDA, and we cannot assure you that
newly discovered or developed safety issues will not arise. With the use of any
of our marketed drugs by a wide patient population, serious adverse events may
occur from time to time that initially do not appear to relate to the drug
itself, and only if the specific event occurs with some regularity over a
period of time does the drug become suspect as having a causal relationship to
the adverse event. Any safety issues could cause us to suspend or cease
marketing of our approved products, subject us to substantial liabilities, and
adversely affect our revenues and financial condition.
Moreover, the marketing of
our approved products will be subject to extensive regulatory requirements
administered by the FDA and other regulatory bodies, including adverse event
reporting requirements and the FDAs general prohibition against promoting
products for unapproved uses. The manufacturing facilities for our approved
products are also subject to continual review and periodic inspection and
approval of manufacturing modifications. Manufacturing facilities that
manufacture drug products for the United States market, whether they are
located inside or outside the United States, are subject to biennial
inspections by the FDA and must comply with the FDAs current good
manufacturing practice, or cGMP, regulations. The FDA stringently applies
regulatory standards for manufacturing. Failure to comply with any of these
post-approval requirements can, among other things, result in warning letters,
product seizures, recalls, fines, injunctions, suspensions or revocations of
marketing licenses, operating restrictions and criminal prosecutions. Any of
these enforcement actions, any unanticipated changes in existing regulatory
requirements or the adoption of new requirements, or any safety issues that arise
with any approved products, could adversely affect our ability to market
products and generate revenues and thus adversely affect our ability to
continue our business.
The manufacturers of our
products and drug candidates also are subject to numerous federal, state, local
and foreign laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard control and
hazardous substance disposal. In the future, our manufacturers may incur
significant costs to comply with those laws and regulations, which could
increase our manufacturing costs and reduce our ability to operate profitably.
We currently do not manufacture our own drug products or drug
candidates and may not be able to obtain adequate supplies, which could cause
delays, subject us to product shortages, or reduce product sales.
The manufacturing of
sufficient quantities of newly-approved drug products and drug candidates is a
time-consuming and complex process. We currently have no manufacturing
capabilities. In order to successfully commercialize our products, including
BYETTA and SYMLIN, and continue to develop our drug candidates, including
exenatide LAR, we rely on various third parties to provide the necessary
manufacturing.
There are a limited number
of manufacturers that operate under the FDAs cGMP regulations capable of
manufacturing for us. In addition, there are a limited number of peptide
suppliers, cartridge manufacturers and disposable pen manufacturers. If we are
not able to arrange for and maintain third-party manufacturing on commercially
reasonable terms, or we lose one of our sole source suppliers used for our
existing products or for some components of our manufacturing processes for our
products or drug candidates, we may not be able to market our products or
complete development of our drug candidates on a timely basis, if at all.
Reliance on third-party
manufacturers limits our ability to control certain aspects of the
manufacturing process and therefore exposes us to a variety of significant
risks, including, but not limited to, risks to our ability to commercialize our
products or conduct clinical trials, risks of reliance on the third-party for
regulatory compliance and quality assurance, third-party refusal to supply on a
long-term basis, the possibility of breach of the manufacturing agreement by
the third-party and the possibility of termination or non-renewal of the
agreement by the third-party, based on its business priorities, at a time that
is costly or inconvenient for us. If any of these risks occur, our product
supply will be interrupted resulting in lost or delayed revenues and delayed
clinical trials. Our reliance on third-party manufacturers for the production
of our two commercial products is described in more detail below.
We rely on Bachem
California, or Bachem, and Mallinckrodt, Inc., or Mallinckrodt, to manufacture
our long-term commercial supply of bulk exenatide, the active ingredient in
BYETTA. In addition, we rely on single-source manufacturers for some of our raw
materials used by Bachem and Mallinckrodt to produce bulk exenatide. We also
rely on Wockhardt UK (Holdings) Ltd., or Wockhardt, and Baxter Pharmaceutical
Solutions LLC, a subsidiary of Baxter, Inc., or Baxter, to
21
manufacture the dosage form
of BYETTA in cartridges. We are further dependent upon Lilly to supply pens for
delivery of BYETTA in cartridges.
We rely on Bachem and Lonza
Ltd. to manufacture our commercial supply of bulk pramlintide acetate, the
active ingredient contained in SYMLIN. In addition, we rely on Baxter to
manufacture the dosage form of SYMLIN in vials. We recently received FDA
approval of a disposable pen for the delivery of SYMLIN in cartridges, and plan
to make the SYMLIN pen available to patients in late 2007 or early 2008. We
will rely on Wockhardt for the dosage form of SYMLIN in cartridges and Ypsomed
AG to manufacture the components for the SYMLIN disposable pen. We will also
rely on Hollister-Stier Laboratories LLC for the assembly of the SYMLIN pen.
If any of our existing or
future manufacturers cease to manufacture or are otherwise unable to timely
deliver sufficient quantities of BYETTA or SYMLIN, in either bulk or dosage
form, or other product components, including pens for the delivery of these
products, it could disrupt our ability to market our products, subject us to
product shortages, reduce product sales and/or reduce our profit margins. Any
delay or disruption in the manufacturing of bulk product, the dosage form of
our products or other product components, including pens for delivery of our
products, could also harm our reputation in the medical and patient
communities. In addition, we may need to engage additional manufacturers so
that we will be able to continue our commercialization and development efforts
for these products or drug candidates. The cost and time to establish these new
manufacturing facilities would be substantial.
Our manufacturers have not
produced BYETTA or SYMLIN for commercial use for a sustained period of time. As
such, additional unforeseeable risks may be encountered as we, together with
our manufacturers, continue to develop familiarity and experience with regard
to manufacturing our products. Furthermore, we and the other manufacturers used
for our drug candidates may not be able to produce supplies in commercial
quantities if our drug candidates are approved. While we believe that business
relations between us and our manufacturers are generally good, we cannot
predict whether any of the manufacturers that we may use will meet our
requirements for quality, quantity or timeliness for the manufacture of bulk
exenatide or pramlintide acetate, dosage form of BYETTA or SYMLIN, or pens.
Therefore, we may not be able to obtain necessary supplies of products with
acceptable quality, on acceptable terms or in sufficient quantities, if at all.
Our dependence on third parties for the manufacture of products may also reduce
our gross profit margins and our ability to develop and deliver products in a
timely manner.
In order to manufacture on a
commercial scale the once-weekly formulation of exenatide LAR, if it is
approved by the FDA, we must design, construct, commission and validate a new
facility. We are dependent on Alkermes and Parsons to assist us in the design,
construction and validation of the manufacturing facility. We have never
established or operated a manufacturing facility and cannot assure you that we
will be able to successfully establish or operate such a facility in a timely
or economical manner, or at all. In addition, we are dependent on Alkermes to
successfully develop and transfer to us its technology for manufacturing the
once-weekly formulation of exenatide LAR. Although we have completed
manufacturing scale-up to intermediate batch size, and together with Alkermes
we have completed engineering batches of commercial scale at a third party
facility, we cannot be assured that a commercial scale manufacturing process
for exenatide LAR will be successfully developed and/or transferred to us in a
timely or economical manner, or at all. In addition, we are dependent on
Alkermes to supply us with commercial quantities of the polymer required to
manufacture exenatide LAR. We also will need to obtain sufficient supplies of diluents,
solvents, devices, packaging and other components necessary for commercial
manufacture of exenatide LAR. If we, together with Alkermes, are unable to
successfully develop a commercial scale manufacturing process and increase our
manufacturing scale to a commercially viable level, we may not be able to
commercially launch exenatide LAR.
Our ability to generate revenues will be diminished if we fail to
obtain acceptable prices or an adequate level of reimbursement for our products
from third-party payors.
The continuing efforts of
government, private health insurers and other third-party payors to contain or
reduce the costs of health care through various means, including efforts to
increase the amount of patient co-pay obligations, may limit our commercial
opportunity. In the United States, we expect that there will continue to be a
number of federal and state proposals to implement government control over the
pricing of prescription pharmaceuticals. In addition, increasing emphasis on
managed care in the United States will continue to put pressure on the rate of
adoption and pricing of pharmaceutical products.
Significant uncertainty
exists as to the reimbursement status of health care products. Third-party
payors, including Medicare, are challenging the prices charged for medical
products and services. Government and other third-party payors increasingly are
attempting to contain health care costs by limiting both coverage and the level
of reimbursement for new drugs and by refusing to provide coverage for uses of
approved products for disease indications for which the FDA has not granted
labeling approval. Third-party insurance coverage may not be available to
patients for BYETTA and/or SYMLIN or any other products we discover and
develop. If government and other third-party payors do not provide adequate
coverage and reimbursement levels for our products, the market acceptance of
these products may be reduced.
22
Competition in the biotechnology and pharmaceutical industries may
result in competing products, superior marketing of other products and lower
revenues or profits for us.
There are many companies
that are seeking to develop products and therapies for the treatment of
diabetes and other metabolic disorders. Our competitors include multinational
pharmaceutical and chemical companies, specialized biotechnology firms and
universities and other research institutions. A number of our largest
competitors, including AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline,
Lilly, Merck & Co., Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis and
Takeda Pharmaceuticals, are pursuing the development or marketing of
pharmaceuticals that target the same diseases that we are targeting, and it is
possible that the number of companies seeking to develop products and therapies
for the treatment of diabetes, obesity and other metabolic disorders will
increase. Many of our competitors have substantially greater financial,
technical, human and other resources than we do and may be better equipped to
develop, manufacture and market technologically superior products. In addition,
many of these competitors have significantly greater experience than we do in
undertaking preclinical testing and human clinical studies of new pharmaceutical
products and in obtaining regulatory approvals of human therapeutic products.
Accordingly, our competitors may succeed in obtaining FDA approval for superior
products. Furthermore, now that we have received FDA approval for BYETTA and
SYMLIN, we may also be competing against other companies with respect to our
manufacturing and product distribution efficiency and sales and marketing
capabilities, areas in which we have limited or no experience as an
organization.
Our target patient
population for BYETTA includes people with diabetes who have not achieved
adequate glycemic control using metformin, sulfonylurea and/or a TZD, the three
most common oral therapies for type 2 diabetes. Our target population for
SYMLIN is people with either type 2 or type 1 diabetes whose therapy includes
multiple mealtime insulin injections daily. Other products are currently in
development or exist in the market that may compete directly with the products
that we are developing or marketing. Various other products are available or in
development to treat type 2 diabetes, including:
sulfonylureas;
metformin;
insulins,
including injectable and inhaled versions;
TZDs;
glinides;
DPP-IV
inhibitors;
incretin/GLP-1
agonists;
CB-1
antagonists;
PPARs;
and
alpha-glucosidase
inhibitors.
In addition, several
companies are developing various approaches to improve treatments for type 1
and type 2 diabetes. We cannot predict whether our products will have
sufficient advantages to cause health care professionals to adopt them over
other products or that our products will offer an economically feasible
alternative to other products. Our products could become obsolete before we
recover expenses incurred in developing these products.
Delays in the conduct or completion of our clinical trials, the
analysis of the data from our clinical trials or our manufacturing scale-up
activities may result in delays in our planned filings for regulatory
approvals, and may adversely affect our ability to enter into new collaborative
arrangements.
We cannot predict whether we
will encounter problems with any of our completed, ongoing or planned clinical
studies that will cause us to delay or suspend our ongoing and planned clinical
studies, delay the analysis of data from our completed or ongoing clinical
studies or perform additional clinical studies prior to receiving necessary
regulatory approvals. We also cannot predict whether we will encounter delays
or an inability to create manufacturing processes for drug candidates that
allow us to produce drug product in sufficient quantities to be economical,
otherwise known as manufacturing scale-up.
23
If the results of our
ongoing or planned clinical studies for our drug candidates are not available
when we expect or if we encounter any delay in the analysis of data from our
clinical studies or if we encounter delays in our ability to scale-up our
manufacturing processes:
we
may be unable to complete our development programs for exenatide LAR or our
obesity clinical trials;
we
may have to delay or terminate our planned filings for regulatory approval;
we
may not have the financial resources to continue research and development of
any of our drug candidates; and
we
may not be able to enter into, if we chose to do so, any additional
collaborative arrangements.
In addition, Lilly can
terminate our collaboration for the development and commercialization of BYETTA
and sustained-release formulations of exenatide at any time on 60 days notice. Furthermore,
if the FDA does not accept for filing an NDA for a sustained-release
formulation of exenatide by December 31, 2007 Lilly may elect to convert
potential future milestone payments that we may receive under our collaboration
agreement into shares of our common stock for up to 60 days following December
31, 2007. The conversion price will equal the immediately preceding twenty day
average closing market price of the Companys common stock on the date of such
election to convert. We currently do not expect the NDA to be filed by this
date.
Any of the following could
delay the completion of our ongoing and planned clinical studies:
ongoing
discussions with the FDA or comparable foreign authorities regarding the scope
or design of our clinical trials;
delays
in enrolling volunteers;
lower
than anticipated retention rate of volunteers in a clinical trial;
negative
results of clinical studies;
insufficient
supply or deficient quality of drug candidate materials or other materials
necessary for the performance of clinical trials;
our
inability to reach agreement with Lilly regarding the scope, design, conduct or
costs of clinical trials with respect to BYETTA, exenatide LAR or nasal
exenatide; or
serious
side effects experienced by study participants relating to a drug candidate.
We are substantially dependent on our collaboration with Lilly for the
development and commercialization of BYETTA and dependent on Lilly and Alkermes
for the development of exenatide LAR.
We have entered into a
collaborative arrangement with Lilly, who currently markets diabetes therapies
and is developing additional diabetes drug candidates, to commercialize BYETTA
and further develop sustained-release formulations of BYETTA, including exenatide
LAR. We entered into this collaboration in order to:
fund
some of our research and development activities;
assist
us in seeking and obtaining regulatory approvals; and
assist
us in the successful commercialization of BYETTA and exenatide LAR.
In general, we cannot
control the amount and timing of resources that Lilly may devote to our
collaboration. If Lilly fails to assist in the further development of exenatide
LAR or the commercialization of BYETTA, or if Lillys efforts are not effective,
our business may be negatively affected. We are relying on Lilly to obtain
regulatory approvals for and successfully commercialize BYETTA and exenatide
LAR outside the United States. Our collaboration with Lilly may not continue or
result in additional successfully commercialized drugs. Lilly can terminate our
collaboration at any time upon 60 days notice. If Lilly ceased funding and/or
developing and commercializing BYETTA or exenatide LAR, we would have to seek
additional sources for funding and may have to delay, reduce or eliminate one
or more of our commercialization and development programs for these compounds.
We are also dependent on Alkermes for the development of exenatide LAR. If
Alkermes technology is not successfully developed to effectively deliver
exenatide in a sustained release formulation, or Alkermes does not devote
sufficient resources to the collaboration, our efforts to develop sustained
release formulations of exenatide could be delayed or curtailed.
24
If our patents
are determined to be unenforceable or if we are unable to obtain new patents
based on current patent applications or for future inventions, we may not be
able to prevent others from using our intellectual property. If we are unable
to obtain licenses to third party patent rights for required technologies, we
could be adversely affected.
We own or hold exclusive rights to many issued
United States patents and pending United States patent applications related to
the development and commercialization of exenatide, including BYETTA and
exenatide LAR, SYMLIN and our other drug candidates. These patents and
applications cover composition-of-matter, medical indications, methods of use,
formulations and other inventive results. We have issued and pending
applications for formulations of BYETTA and exenatide LAR, but we do not have a
composition-of-matter patent covering exenatide. We also own or hold exclusive
rights to various foreign patent applications that correspond to issued United
States patents or pending United States patent applications.
Our success will depend in part on our ability to
obtain patent protection for our products and drug candidates and technologies
both in the United States and other countries. We cannot guarantee that any
patents will issue from any pending or future patent applications owned by or
licensed to us. Alternatively, a third party may successfully challenge or
circumvent our patents. Our rights under any issued patents may not provide us
with sufficient protection against competitive products or otherwise cover
commercially valuable products or processes. In addition, because patent
applications in the United States are maintained in secrecy for eighteen months
after the filing of the applications, and publication of discoveries in the
scientific or patent literature often lag behind actual discoveries, we cannot
be sure that the inventors of subject matter covered by our patents and patent
applications were the first to invent or the first to file patent applications
for these inventions. Third parties have filed, and in the future are likely to
file, patent applications on inventions similar to ours. From time-to-time we
have participated in, and in the future are likely to participate in, interference
proceedings declared by the United States Patent and Trademark Office to
determine priority of invention, which could result in a loss of our patent
position. We may also have to participate in opposition proceedings against our
patents in other jurisdictions, such as Europe. Furthermore, we may not have
identified all United States and foreign patents that pose a risk of
infringement.
We also rely upon licensing opportunities for some
of our technologies. We cannot be certain that we will not lose our rights to
certain patented technologies under existing licenses or that we will be able
to obtain a license to any required third-party technology. If we lose our
licensed technology rights or if we are not able to obtain a required license,
we could be adversely affected.
We may be unable
to obtain regulatory clearance to market our drug candidates in the United
States or foreign countries on a timely basis, or at all.
Our drug candidates are subject to extensive
government regulations related to development, clinical trials, manufacturing
and commercialization. The process of obtaining FDA and other regulatory
approvals is costly, time-consuming, uncertain and subject to unanticipated
delays. Regulatory authorities may refuse to approve an application for
approval of a drug candidate if they believe that applicable regulatory
criteria are not satisfied. Regulatory authorities may also require additional
testing for safety and efficacy. Moreover, if the FDA grants regulatory
approval of a product, the approval may be limited to specific indications or
limited with respect to its distribution, and expanded or additional
indications for approved drugs may not be approved, which could limit our
revenues. Foreign regulatory authorities may apply similar limitations or may
refuse to grant any approval. Unexpected changes to the FDA or foreign
regulatory approval process could also delay or prevent the approval of our
drug candidates.
The data collected from our
clinical trials may not be sufficient to support approval of our drug
candidates or additional or expanded indications by the FDA or any foreign
regulatory authorities. Biotechnology stock prices have declined significantly
in certain instances where companies have failed to meet expectations with respect
to FDA approval or the timing for FDA approval. If the FDAs or any foreign
regulatory authoritys response is delayed or not favorable for any of our drug
candidates, our stock price could decline significantly.
Moreover, manufacturing
facilities operated by the third-party manufacturers with whom we may contract
to manufacture our unapproved drug candidates may not pass an FDA or other
regulatory authority preapproval inspection. Any failure or delay in obtaining
these approvals could prohibit or delay us or any of our business partners from
marketing these drug candidates.
Consequently, even if we
believe that preclinical and clinical data are sufficient to support regulatory
approval for our drug candidates, the FDA and foreign regulatory authorities
may not ultimately approve our drug candidates for commercial sale in any
jurisdiction. If our drug candidates are not approved, our ability to generate
revenues may be limited and our business will be adversely affected.
25
Litigation regarding patents and other proprietary rights may be
expensive, cause delays in bringing products to market and harm our ability to
operate.
Our success will depend in part on our ability to
operate without infringing the proprietary rights of third parties and
preventing others from infringing our patents. Challenges by pharmaceutical
companies against the patents of competitors are common. Legal standards
relating to the validity of patents covering pharmaceutical and
biotechnological inventions and the scope of claims made under these patents
are still developing. As a result, our ability to obtain and enforce patents is
uncertain and involves complex legal and factual questions. Third parties may
challenge, in courts or through patent office proceedings, or infringe upon,
existing or future patents. In the event that a third party challenges a
patent, a court or patent office may invalidate the patent or determine that
the patent is not enforceable. Proceedings involving our patents or patent
applications or those of others could result in adverse decisions about:
the
patentability of our inventions, products and drug candidates; and/or
the
enforceability, validity or scope of protection offered by our patents.
The manufacture, use or sale of any of our products
or drug candidates may infringe on the patent rights of others. If we are
unable to avoid infringement of the patent rights of others, we may be required
to seek a license, defend an infringement action or challenge the validity of
the patents in court. Patent litigation is costly and time consuming. We may
not have sufficient resources to bring these actions to a successful
conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing
technology, fail to successfully defend an infringement action or have
infringing patents declared invalid, we may:
incur
substantial monetary damages;
encounter
significant delays in bringing our drug candidates to market; and/or
be
precluded from participating in the manufacture, use or sale of our products or
drug candidates or methods of treatment requiring licenses.
We are subject to fraud and abuse
and similar laws and regulations, and a failure to comply with such regulations
or prevail in any litigation related to noncompliance could harm our business.
Upon approval of BYETTA and
SYMLIN by the FDA, we became subject to various health care fraud and abuse
laws, such as the Federal False Claims Act, the federal anti-kickback statute
and other state and federal laws and regulations. Pharmaceutical companies have
faced lawsuits and investigations pertaining to violations of these laws and
regulations. We cannot guarantee that measures that we have taken to prevent
such violations, including our corporate compliance program, will protect us
from future violations, lawsuits or investigations. If any such actions are
instituted against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact on our
business, including the imposition of significant fines or other sanctions.
Our financial results will fluctuate, and these fluctuations may cause
our stock price to fall.
Forecasting future revenues
is difficult, especially since we launched our first products in 2005 and when
the level of market acceptance of these products may change rapidly. In
addition, our customer base is highly concentrated with four customers
accounting for most of our net product sales. Fluctuations in the buying
patterns of these customers, which may result from seasonality, wholesaler
buying decisions or other factors outside of our control, could significantly
affect the level of our net sales on a period to period basis. As a result, it
is reasonably likely that our financial results will fluctuate to an extent,
that may not meet with market expectations and that also may adversely affect
our stock price. There are a number of other factors that could cause our
financial results to fluctuate unexpectedly, including:
product
sales;
cost
of product sales;
achievement
and timing of research and development milestones;
collaboration
revenues;
26
cost
and timing of clinical trials, regulatory approvals and product launches;
marketing
and other expenses;
manufacturing
or supply issues; and
potential
acquisitions of businesses and technologies and our ability to successfully
integrate any such acquisitions into our existing business.
We may require additional financing in the future, which may not be
available to us on favorable terms, or at all.
We intend to use our
available cash for:
Commercialization
of BYETTA and SYMLIN;
Establishment
of additional manufacturing sources, including our Ohio manufacturing facility;
Development
of exenatide LAR and other pipeline candidates;
Executing
our INTO strategy;
Our
other research and development activities;
Other
operating expenses;
Potential
acquisitions or investments in complementary technologies or businesses; and
Other
general corporate purposes.
We may also be required to
use our cash to pay principal and interest on outstanding debt, including $775
million in outstanding principal amount of convertible senior notes, of which
$200 million is due in 2011 and $575 million is due in 2014.
Our business has a substantial risk of product liability claims, and
insurance may not be adequate to cover these claims.
Our business exposes us to
potential product liability risks that are inherent in the testing,
manufacturing and marketing of human therapeutic products. Product liability
claims could result in the imposition of substantial liability on us, a recall
of products, or a change in the indications for which they may be used. We
currently have limited product liability insurance coverage. We cannot assure
you that our insurance will provide adequate coverage against potential
liabilities.
Our ability to enter into and maintain third-party relationships is
important to our successful development and commercialization of BYETTA, SYMLIN
and our other drug candidates and to our potential profitability.
With respect to sales,
marketing and distribution outside the United States, we will be substantially
dependent on Lilly for activities relating to BYETTA and sustained-release
formulations of BYETTA, including exenatide LAR. We believe that we will likely
need to enter into marketing and distribution arrangements with third parties
for, or find a corporate partner who can provide support for, the development
and commercialization of SYMLIN or our other drug candidates outside the United
States. We may also enter into arrangements with third parties for the
commercialization of SYMLIN or any of our other drug candidates within the
United States.
With respect to BYETTA and,
if approved, exenatide LAR, Lilly is co-promoting within the United States. If
Lilly ceased commercializing BYETTA or, if approved, exenatide LAR, for any reason,
we would likely need to either enter into a marketing and distribution
arrangement with a third party for those products or significantly increase our
internal sales and commercialization infrastructure.
We may not be able to enter
into marketing and distribution arrangements or find a corporate partner for
SYMLIN or our other drug candidates as we deem necessary. If we are not able to
enter into a marketing or distribution arrangement or find a corporate partner
who can provide support for commercialization of our drug candidates as we deem
necessary, we may not be able to successfully perform these marketing or
distribution activities. Moreover, any new marketer or distributor
27
or corporate partner for our
drug candidates, including Lilly, with whom we choose to contract may not
establish adequate sales and distribution capabilities or gain market
acceptance for our products, if any.
We have a significant amount of indebtedness. We may not be able to
make payments on our indebtedness, and we may incur additional indebtedness in
the future, which could adversely affect our operations.
In April 2004, we issued
$200 million of the 2004 Notes and in June 2007, we issued $575 million of the
2007 Notes. Our ability to make payments on our debt, including the 2004 and
2007 Notes, will depend on our future operating performance and ability to
generate cash and may also depend on our ability to obtain additional debt or
equity financing. During each of the last five years, our operating cash flows
were negative and insufficient to cover our fixed charges. We may need to use
our cash to pay principal and interest on our debt, thereby reducing the funds
available to fund our research and development programs, strategic initiatives
and working capital requirements. Our ability to generate sufficient operating
cash flow to service our indebtedness, including the 2004 and 2007 Notes, and
fund our operating requirements will depend on our ability, alone or with
others, to successfully develop, manufacture, obtain required regulatory
approvals for and market our drug candidates, as well as other factors,
including general economic, financial, competitive, legislative and regulatory
conditions, some of which are beyond our control. Our debt service obligations
increase our vulnerabilities to competitive pressures, because many of our
competitors are less leveraged than we are. If we are unable to generate
sufficient operating cash flow to service our indebtedness and fund our
operating requirements, we may be forced to reduce our development programs,
sell assets or seek additional debt or equity financing, which may not be
available to us on satisfactory terms or at all. Our level of indebtedness may
make us more vulnerable to economic or industry downturns. If we incur new
indebtedness, the risks relating to our business and our ability to service our
indebtedness will intensify.
We may be required to redeem our convertible senior notes upon a
designated event.
Holders of the 2004 and 2007
Notes may require us to redeem all or any portion of their notes upon the
occurrence of certain designated events which generally involve a change in
control of our company. We may not have sufficient cash funds to redeem the notes
upon a designated event. We may elect, subject to certain conditions, to pay
the redemption price for the 2004 Notes in our common stock or a combination of
cash and our common stock. We may be unable to satisfy the requisite conditions
to enable us to pay some or all of the redemption price for the 2004 Notes in
our common stock. In addition, although there are currently no restrictions on
our ability to pay the redemption price under our existing debt agreements,
future debt agreements may prohibit us from repaying the redemption price of
either of the notes in either cash or common stock. If we are prohibited from
redeeming the 2004 Notes or 2007 Notes, we could seek consent from our lenders
to redeem the notes. If we are unable to obtain their consent, we could attempt
to refinance the notes. If we were unable to obtain a consent or refinance, we
would be prohibited from redeeming the notes. If we were unable to redeem the
notes upon a designated event, it would result in an event of default under the
indentures governing the notes. An event of default under the indentures could
result in a further event of default under our other then-existing debt. In
addition, the occurrence of a designated event may be an event of default under
our other debt.
If our research and development programs fail to result in additional
drug candidates, the growth of our business could be impaired.
Certain of our research and
development programs for drug candidates are at an early stage and will require
significant research, development, preclinical and clinical testing,
manufacturing scale-up activities, regulatory approval and/or commitments of
resources before commercialization. We cannot predict whether our research will
lead to the discovery of any additional drug candidates that could generate
additional revenues for us.
Our future success depends on our chief executive officer, and other
key executives and our ability to attract, retain and motivate qualified
personnel.
We are highly dependent on
our chief executive officer, and the other principal members of our executive
and scientific teams. The unexpected loss of the services of any of these
persons might impede the achievement of our research, development and
commercialization objectives. Recruiting and retaining qualified sales,
marketing, regulatory, scientific and other personnel and consultants will also
be critical to our success. We may not be able to attract and retain these
personnel and consultants on acceptable terms given the competition between numerous
pharmaceutical and biotechnology companies. We do not maintain key person
insurance on any of our employees.
We may be unable to adequately prevent disclosure of trade secrets and
other proprietary information.
In order to protect our
proprietary technology and processes, we rely in part on confidentiality
agreements with our corporate partners, employees, consultants, manufacturers,
outside scientific collaborators and sponsored researchers and
28
other advisors. These
agreements may not effectively prevent disclosure of confidential information
and may not provide an adequate remedy in the event of unauthorized disclosure
of confidential information. In addition, others may independently discover our
trade secrets and proprietary information.
Costly and time-consuming
litigation could be necessary to enforce and determine the scope of our
proprietary rights, and failure to obtain or maintain trade secret protection
could adversely affect our competitive business position.
Our research and development activities and planned manufacturing
activities involve the use of hazardous materials, which subject us to
regulation, related costs and delays and potential liabilities.
Our research and development
and our planned manufacturing activities involve the controlled use of
hazardous materials, chemicals and various radioactive compounds. Although we
believe that our research and development safety procedures for handling and
disposing of these materials comply with the standards prescribed by state and
federal regulations, the risk of accidental contamination or injury from these
materials cannot be eliminated. In addition, as part of the development of our
planned manufacturing activities, we will need to develop additional safety
procedures for the handling and disposing of hazardous materials. If an
accident occurs, we could be held liable for resulting damages, which could be
substantial. We are also subject to numerous environmental, health and workplace
safety laws and regulations, including those governing laboratory procedures,
exposure to blood-borne pathogens and the handling of biohazardous materials.
Additional federal, state and local laws and regulations affecting our
operations may be adopted in the future. We may incur substantial costs to
comply with, and substantial fines or penalties if we violate, any of these
laws or regulations.
We are exposed to potential risks from recent legislation requiring
companies to evaluate internal control over financial reporting.
The Sarbanes-Oxley Act
requires that we report annually on the effectiveness of our internal control
over financial reporting. Among other things, we must perform systems and
processes evaluation and testing. We must also conduct an assessment of our
internal control to allow management to report on, and our independent
registered public accounting firm to attest to, our assessment of our internal
control over financial reporting, as required by Section 404 of the
Sarbanes-Oxley Act. In connection with our Section 404 compliance efforts, we
have incurred or expended, and expect to continue to incur or expend,
substantial accounting and other expenses and significant management time and
resources. We have implemented certain remediation activities resulting from
our ongoing assessment of internal control over financial reporting. Our future
assessment, or the future assessments by our independent registered public
accounting firm, may reveal material weaknesses in our internal control. If
material weaknesses are identified in the future we would be required to
conclude that our internal control over financial reporting are ineffective and
we could be subject to sanctions or investigations by the SEC, the NASDAQ Stock
Market or other regulatory authorities, which would require additional
financial and management resources and could adversely affect the market price
of our common stock.
We have implemented anti-takeover provisions that could discourage or
prevent an acquisition of our company, even if the acquisition would be
beneficial to our stockholders, and as a result our management may become
entrenched and hard to replace.
Provisions in our
certificate of incorporation and bylaws could make it more difficult for a
third party to acquire us, even if doing so would benefit our stockholders.
These provisions include:
allowing
our board of directors to elect a director to fill a vacancy created by the
expansion of the board of directors;
allowing
our board of directors to issue, without stockholder approval, up to 5.5
million shares of preferred stock with terms set by the board of directors;
limiting
the ability of holders of our outstanding common stock to call a special
meeting of our stockholders; and
preventing
stockholders from taking actions by written consent and requiring all
stockholder actions to be taken at a meeting of our stockholders.
Each of these provisions, as
well as selected provisions of Delaware law, could discourage potential
takeover attempts, could adversely affect the trading price of our securities
and could cause our management to become entrenched and hard to replace. In
addition to provisions in our charter documents and under Delaware law, an
acquisition of our company could be made more difficult by our employee
benefits plans and our employee change in control plan, under which, in
connection with a change in control, stock options held by our employees may
become vested and our officers may receive severance
29
benefits. We also have
implemented a stockholder rights plan, also called a poison pill, which could
make it uneconomical for a third party to acquire us on a hostile basis.
Our executive officers, directors and major stockholders control
approximately 58% of our common stock.
As of September 30, 2007,
executive officers, directors and holders of 5% or more of our outstanding
common stock, in the aggregate, owned or controlled approximately 58% of our
outstanding common stock. As a result, these stockholders are able to influence
all matters requiring approval by our stockholders, including the election of
directors and the approval of corporate transactions. This concentration of
ownership may also delay, deter or prevent a change in control of our company
and may make some transactions more difficult or impossible to complete without
the support of these stockholders.
Substantial future sales of our common stock by us or our existing
stockholders or the conversion of our convertible senior notes to common stock
could cause the trading price of our common stock to fall.
Sales by existing
stockholders of a large number of shares of our common stock in the public
market or the perception that additional sales could occur could cause the trading
price of our common stock to drop. Likewise, the issuance of shares of common
stock upon conversion of our convertible notes or redemption of our convertible
notes upon a designated event, or upon additional convertible debt or equity
financings or other share issuances by us, including shares issued in
connection with potential future strategic alliances and the uncertain number
of additional shares that we may be required to issue under our agreements with
Lilly, could adversely affect the trading price of our common stock. Our
convertible notes are currently convertible into a total of up to 15.2 million
shares. In addition, the existence of these notes may encourage short selling
of our common stock by market participants.
Significant volatility in the market price for our common stock could
expose us to litigation risk.
The market prices for
securities of biopharmaceutical and biotechnology companies, including our
common stock, have historically been highly volatile, and the market from time
to time has experienced significant price and volume fluctuations that are
unrelated to the quarterly operating performance of these biopharmaceutical and
biotechnology companies. Since January 1, 2005, the high and low sales price of
our common stock varied significantly, as shown in the following table:
|
|
High
|
|
Low
|
|
Year ending December 31, 2007
|
|
|
|
|
|
Fourth Quarter (through October 29, 2007)
|
|
$
|
51.10
|
|
$
|
43.91
|
|
Third Quarter
|
|
$
|
53.25
|
|
$
|
40.86
|
|
Second Quarter
|
|
$
|
46.93
|
|
$
|
36.91
|
|
First Quarter
|
|
$
|
42.45
|
|
$
|
35.55
|
|
Year ended December 31, 2006
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
48.48
|
|
$
|
35.74
|
|
Third Quarter
|
|
$
|
51.54
|
|
$
|
40.76
|
|
Second Quarter
|
|
$
|
49.37
|
|
$
|
38.16
|
|
First Quarter
|
|
$
|
49.08
|
|
$
|
35.58
|
|
Year ended December 31, 2005
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
42.36
|
|
$
|
32.63
|
|
Third Quarter
|
|
$
|
35.47
|
|
$
|
18.50
|
|
Second Quarter
|
|
$
|
21.73
|
|
$
|
14.50
|
|
First Quarter
|
|
$
|
24.95
|
|
$
|
17.15
|
|
Given the uncertainty of our
future funding, whether BYETTA and SYMLIN will meet our expectations, and the
regulatory approval of our other drug candidates, we may continue to experience
volatility in our stock price for the foreseeable future. In addition, the
following factors may significantly affect the market price of our common
stock:
our
financial results and/or fluctuations in our financial results;
safety
issues with BYETTA, SYMLIN or our product candidates;
clinical
study results;
determinations
by regulatory authorities with respect to our drug candidates;
30
our
ability to complete our Ohio manufacturing facility and the commercial
manufacturing process for exenatide LAR;
developments
in our relationships with current or future collaborative partners;
our
ability to successfully execute our commercialization strategies;
developments
in our relationships with third-party manufacturers of our products and other
parties who provide services to us;
technological
innovations or new commercial therapeutic products by us or our competitors;
developments
in patent or other proprietary rights; and
governmental
policy or regulation, including with respect to pricing and reimbursement.
Broad market and industry
factors also may materially adversely affect the market price of our common
stock, regardless of our actual operating performance. Periods of volatility in
the market price of our common stock expose us to securities class-action
litigation, and we may be the target of such litigation as a result of market
price volatility in the future.
31
ITEM 6. Exhibits
The following exhibits are
included as part of this report:
Exhibit
Number
|
|
Description
|
|
|
|
3.1
|
|
Amended and Restated
Certificate of Incorporation (filed as an exhibit to Registrants
registration statement on Form S-1 (File No. 333-44195) or
amendments thereto and incorporated herein by reference)
|
|
|
|
3.2
|
|
Third Amended and
Restated Bylaws (filed as an exhibit to Registrants Current Report on Form
8-K filed on October 31, 2007 and incorporated herein by reference)
|
|
|
|
3.3
|
|
Certificate of
Amendment of Amended and Restated Certificate of Incorporation (filed as an
exhibit to Registrants Quarterly Report on Form 10-Q for the quarter
ended September 30, 2001 and incorporated herein by reference)
|
|
|
|
3.4
|
|
Certificate of
Amendment of Amended and Restated Certificate of Incorporation (filed as an
exhibit to Registrants Quarterly Report on Form 10-Q for the quarter ended
June 30, 2007 and incorporated herein by reference)
|
|
|
|
4.1
|
|
Specimen Common Stock
Certificate (filed as an exhibit to Registrants registration statement on
Form S-1 (File No. 333-44195) or amendments thereto and incorporated
herein by reference)
|
|
|
|
4.2
|
|
Rights Agreement, dated
as of June 17, 2002, between the Registrant and American Stock
Transfer & Trust Company (filed as an exhibit to Registrants
Current Report on Form 8-K filed on June 18, 2002 and incorporated
herein by reference)
|
|
|
|
4.3
|
|
First Amendment to
Rights Agreement dated December 13, 2002, between the Registrant and
American Stock Transfer & Trust Company (filed as an exhibit to
Registrants Annual Report on Form 10-K for the fiscal year ended
December 31, 2002 and incorporated herein by reference)
|
|
|
|
4.4
|
|
Form of Rights
Certificate (filed as an exhibit to Registrants Current Report on
Form 8-K filed on June 18, 2002 and incorporated herein by
reference)
|
|
|
|
4.5
|
|
Certificate of
Designation of Series A Junior Participating Preferred Stock (filed as
an exhibit to Registrants Current Report on Form 8-K filed on
June 18, 2002 and incorporated herein by reference)
|
|
|
|
31.1
|
|
Certification of
Principal Financial Officer pursuant to Rule 13a-14(a) and
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
|
|
|
|
31.2
|
|
Certification of
Principal Executive Officer pursuant to Rule 13a-14(a) and
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
|
|
|
|
32.1
|
|
Certifications Pursuant
to U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
32
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Amylin
Pharmaceuticals, Inc.
|
|
|
Date: November 6, 2007
|
By:
|
/S/ MARK G. FOLETTA
|
|
|
Mark
G. Foletta,
|
|
Senior Vice President, Finance and
Chief Financial Officer
(on behalf of the registrant and as the
registrants principal financial and accounting
officer)
|
33
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024